AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH). During advanced peptide synthesis, a tyrosine residue is added to the N-terminus to stabilise the molecule. This modification ensures excellent molecular stability during laboratory handling and storage. As a premium research chemical, UK laboratories utilise AOD-9604 to investigate fat metabolism and lipolysis in isolated adipocytes. In cellular assays, this compound stimulates the breakdown of lipids by upregulating beta-3 adrenergic receptors, without triggering the cellular proliferation pathways typically associated with full-length growth hormone. Researchers can find detailed molecular data on PubChem. To maintain the integrity of the peptide in vitro, scientists must follow strict reconstitution protocols using appropriate buffers. This ensures the lyophilised powder dissolves correctly, allowing for precise and reproducible experimental results.
Current literature uses the search phrase "fat loss" when indexing the lipolytic properties of AOD-9604 in laboratory cell cultures. Public search data frequently explores these metabolic pathways, but published papers focus solely on isolated cellular models. Amino Peptides supplies this compound only as a lyophilised laboratory reagent for controlled lab experiments. Strictly for laboratory research.
- Exhibits high-affinity binding to the beta-3 adrenergic receptor (β3-AR) in isolated murine and human adipocyte models.
- Interacts with the growth hormone receptor (GHR) extracellular domain, though with markedly lower affinity than full-length somatotropin in cell-free binding kinetics.
- Modulates downstream G-protein coupled receptor (GPCR) signalling nodes without engaging the prolactin receptor (PRLR) pathways typically activated by unmodified hGH.
- Demonstrates selective binding affinity for lipolytic receptor conformations in immortalised preadipocyte lineages during competitive ligand-binding experiments.
- Upregulates cyclic adenosine monophosphate (cAMP) accumulation in isolated adipocytes, triggering the activation of protein kinase A (PKA) cascades.
- Stimulates the phosphorylation and subsequent activation of hormone-sensitive lipase (HSL) in cell-free lipid droplet models.
- Inhibits the enzymatic activity of acetyl-CoA carboxylase, thereby attenuating de novo lipogenesis in cultured hepatocyte and adipocyte systems.
- Induces lipolysis independently of insulin-like growth factor 1 (IGF-1) transcription, maintaining basal cellular proliferation rates in laboratory models.
Technical Specifications
Variant Breakdown
- 2mg Vial: Ideal for preliminary in-vitro screening and small-scale cellular assays, allowing researchers to establish baseline laboratory evaluation-response curves.
- 5mg Vial: Suited for medium-scale laboratory experiments that require multiple replications across different adipocyte cell lines.
- 10mg Vial: Designed for extensive, long-term biochemical studies, ensuring a consistent and continuous supply of the peptide for high-throughput screening.
Quality Assurance
- HPLC Analysis: High-performance liquid chromatography is utilised to confirm a purity level exceeding 99%, ensuring no unwanted byproducts interfere with cellular assays.
- Mass Spectrometry: Advanced mass spectrometry verifies the exact molecular weight (1815.1 g/mol), confirming the structural identity of the synthesised peptide.
- Lyophilised Form: The compound is supplied as a stable lyophilised solid, which preserves its biochemical integrity during transit and storage.
- Endotoxin Testing: Strict laboratory characterisation ensures endotoxin limits remain below 0.5 EU/mg, preventing inflammatory responses in sensitive cell cultures.
Research Mechanism
- Receptor Interaction: AOD-9604 binds to specific receptors on the surface of isolated fat cells (adipocytes), initiating a signalling cascade that promotes lipid breakdown.
- Lipolysis Activation: The peptide stimulates the release of glycerol and free fatty acids by upregulating beta-3 adrenergic receptor activity in vitro.
- Lipogenesis Inhibition: It actively prevents the formation of new fat droplets within the cell by suppressing the enzymes responsible for lipid storage.
- Independent Pathway: Unlike full-length growth hormone, AOD-9604 does not bind to the primary hGH receptor, meaning it does not induce IGF-1 secretion or affect cellular insulin sensitivity.
Reconstitution & Storage Data
| Vial Strength | Solvent Added | Resulting Concentration |
| 2mg | 1 mL Bacteriostatic Reconstitution Solution | 2.00 mg/mL |
| 2mg | 2 mL Bacteriostatic Reconstitution Solution | 1.00 mg/mL |
| 5mg | 1 mL Bacteriostatic Reconstitution Solution | 5.00 mg/mL |
| 5mg | 2 mL Bacteriostatic Reconstitution Solution | 2.50 mg/mL |
| 10mg | 1 mL Bacteriostatic Reconstitution Solution | 10.00 mg/mL |
| 10mg | 2 mL Bacteriostatic Reconstitution Solution | 5.00 mg/mL |
- Lyophilised (Powder): Store in a standard refrigerator (2-8°C) for up to 3 months. For long-term preservation, freeze at -20°C.
- Reconstituted (Liquid): Store at 2-8°C (Refrigerated).
Scientific References
Endocrinology: "The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic laboratory evaluation in Obese Mice and beta(3)-AR Knock-Out Mice" View Study
Lipids: "In vitro lipolytic activity of a synthetic fragment of human growth hormone" View Study
laboratory evaluation Testing and Analysis: "Detection of the growth hormone-releasing peptide AOD-9604 in human urine" View Study
Biochemical and Biophysical Research Communications: "Antiobesity effects of a synthetic lipolytic peptide" View Study
International Journal of Obesity: "Increase of fat oxidation and laboratory evaluation in obese mice caused by chronic laboratory evaluation with human growth hormone or a modified C-terminal fragment" View Study
